<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047940</url>
  </required_header>
  <id_info>
    <org_study_id>16968</org_study_id>
    <secondary_id>I9J-MC-DIPA</secondary_id>
    <nct_id>NCT04047940</nct_id>
  </id_info>
  <brief_title>A Study of LY900020 in Healthy Chinese Participants</brief_title>
  <official_title>A Relative Bioavailability Study of Three LY900020 Tablet Formulations in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate three new formulations of LY900020; a fixed dose, combination drug
      developed for people with type 2 diabetes mellitus. The study will be conducted in healthy
      participants to investigate the effect of different tablet formulations on the amount of
      LY900020 in the bloodstream. Side effects and tolerability will be documented. The study will
      last about 10 weeks for each participant, including screening and follow up. Screening is
      required within 28 days prior to entering the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Actual">February 18, 2020</completion_date>
  <primary_completion_date type="Actual">February 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY900020</measure>
    <time_frame>Predose through 72 hours postdose on Day 4 in each study arm</time_frame>
    <description>PK: AUC of LY900020</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of LY900020</measure>
    <time_frame>Predose through 72 hours postdose on Day 4 in each study arm</time_frame>
    <description>PK: Cmax of LY900020</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK: Time to Maximum Observed Drug Concentration (tmax) of LY900020</measure>
    <time_frame>Predose through 72 hours postdose on Day 4 in each study arm</time_frame>
    <description>PK: Tmax of LY900020</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY900020 Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY900020 Formulation 1 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900020 Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY900020 Formulation 2 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900020 Formulation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY900020 Formulation 3 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Drugs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin XR, atorvastatin, and valsartan administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900020</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY900020 Formulation 1</arm_group_label>
    <arm_group_label>LY900020 Formulation 2</arm_group_label>
    <arm_group_label>LY900020 Formulation 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Reference Drugs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Reference Drugs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Reference Drugs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy male or a female (not pregnant and agreeable to take birth control
             measures until study completion)

          -  Have a body mass index (BMI) of 18.5 to 35 kilogram per square meter (kg/mÂ²),
             inclusive, at screening

          -  Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine
             laboratory test results that are acceptable for the study

        Exclusion Criteria:

          -  Are currently participating in or completed a clinical trial within the last 30 days
             or any other type of medical research judged to be incompatible with this study

          -  Have previously participated or withdrawn from this study

          -  Have or used to have health problems or laboratory test results or ECG readings that,
             in the opinion of the doctor, could make it unsafe to participate, or could interfere
             with understanding the results of the study

          -  Had blood loss of more than 400 milliliters (mL) within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lilly Centre for Clinical Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 1, 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

